Two or four hour ( 18 F)FMISO-PET in HNSCC is the contrast best?

Summary [ 18 F]Fluoromisonidazole positron emission tomography (FMISO-PET) is a non invasive imaging technique that can assist detecting intra tumour regions of hypoxia. FMISO-PET evinces comparatively low signal-to-noise-ratio (SNR) and may be acquired dynamically or after different uptake times post injection (p. i.). The aim of this study was to identify, if static images acquired two hours (MISO2) or four hours (MISO4) p. i. reveal higher contrast. Patients, methods: As part of a prospective trial, 23 patients with cancers of the head and neck underwent [ 18 F]fluoro deoxyglucose (FDG) PET before and during curative radiochemotherapy. Additionally, FMISO-PET studies 2 h and 4 h p. i. were done before treatment and after a mean dose of 11 Gy, 23 Gy and 57 Gy during RCT. After coregistration, a dedicated software was used to define the gross tumour volume (GTV) by FDG PET for the primary tumour. This volume was overlaid to the FMISO images and hypoxia within the GTV was determined. The contrast between hypoxia determined by MISO2 and by MISO4 was investigated and analysed with the Wilcoxon-matched-pairs test. Results: Mean SUVmax in tumours of all examinations was 2.2 (stdev: 0.4, min: 1.3, max:

[1]  M. Baumann,et al.  Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  F Hofheinz,et al.  Effects of cold sphere walls in PET phantom measurements on the volume reproducing threshold , 2010, Physics in medicine and biology.

[3]  John L. Humm,et al.  Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer , 2010, Journal of Nuclear Medicine.

[4]  Steen Jakobsen,et al.  Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Sigrid Stroobants,et al.  Dose Painting in Radiotherapy for Head and Neck Squamous Cell Carcinoma: Value of Repeated Functional Imaging with 18F-FDG PET, 18F-Fluoromisonidazole PET, Diffusion-Weighted MRI, and Dynamic Contrast-Enhanced MRI , 2009, Journal of Nuclear Medicine.

[6]  L. Dubois,et al.  [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Baumann,et al.  Serial FDG-PET on patients with head and neck cancer: Implications for radiation therapy , 2009, International journal of radiation biology.

[8]  W. Oyen,et al.  Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Sadek Nehmeh,et al.  The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. , 2008, International journal of radiation oncology, biology, physics.

[10]  Roland Bares,et al.  Hypoxia-imaging with 18F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer , 2007 .

[11]  Jörg van den Hoff,et al.  Quantitative 3D ROI volume delineation in PET: Algorithm and validation , 2007 .

[12]  M. Krause,et al.  Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  M. Alber,et al.  Imaging oxygenation of human tumours , 2006, European Radiology.

[14]  Martin Westhofen,et al.  FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  R. Fisher,et al.  Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Simon M. Ametamey,et al.  NanoPET imaging of [18F]fluoromisonidazole uptake in experimental mouse tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Daniela Thorwarth,et al.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.

[18]  Lester J. Peters,et al.  Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Ming-fang Wang,et al.  Fully automated one-pot synthesis of [18F]fluoromisonidazole. , 2005, Nuclear medicine and biology.

[20]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  Jean-François Daisne,et al.  Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. , 2004, Radiology.

[22]  J. Eary,et al.  [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[24]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[25]  A. Nunn,et al.  Nitroimidazoles and imaging hypoxia , 1995, European Journal of Nuclear Medicine.

[26]  D. Hellwig,et al.  Positron emission tomography 2008 in Germany , 2010, Nuklearmedizin.

[27]  Gig Mageras,et al.  Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[28]  R. Ewers,et al.  Uptake of 18F-FLT and 18F-FDG in primary head and neck cancer correlates with survival , 2008, Nuklearmedizin.

[29]  Sadek Nehmeh,et al.  Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.

[30]  W. Oyen,et al.  Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  Kenneth A Krohn,et al.  Imaging hypoxia and angiogenesis in tumors. , 2005, Radiologic clinics of North America.

[32]  L. Adler,et al.  PET imaging in soft tissue sarcomas. , 1997, Cancer treatment and research.

[33]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  K. Krohn,et al.  Synthesis and characterization of congeners of misonidazole for imaging hypoxia. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.